A new steroidal alkylating agent with improved activity in advanced murine leukemias.
The homo-aza-steroidal ester of [p-[bis(2-chloroethyl)amino]phenoxy] acetic acid, 3 beta-hydroxy 13 alpha - amino - 13,17 - seco - 5 alpha-androstan-17-oic-13,17-lactam-p-bis(2-chloroethyl)aminophenoxyacetate, gave a 100% increase in lifespan over controls in the treatment of L1210 leukemia by IP administration on a days 1 and 4 treatment schedule. This ester gave a maximum activity of 383% increased lifespan over controls in the treatment of P388 leukemia by IP administration on a daily treatment schedule. Activity in advanced L1210 (41% increased lifespan) and P388 leukemias (173% increased lifespan) was maintained, indicating that this compound is the most promising of a number of congeners tested to date.
D000477:Alkylating Agents / Q000627:therapeutic use*; D000818:Animals; D001378:Azasteroids / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D013260:Steroids, Heterocyclic / Q000627:therapeutic use*; D013997:Time Factors
D000477:Alkylating Agents; D001378:Azasteroids; D009588:Nitrogen Mustard Compounds; D013260:Steroids, Heterocyclic; C017888:NSC 290205